The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort
Abstract
Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. A recent large cohort study showed effects of similar magnitude for different types of progestogens and for different routes of administration of estrogens evaluated. Further investigation of these issues is of importance. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT 1 year before entering the E3N‐EPIC cohort study (mean age at inclusion: 52.8 years); 948 primary invasive breast cancers were diagnosed during follow‐up (mean duration: 5.8 years). Data were analyzed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared to nonusers was found (relative risk (RR) 1.2 [95% confidence interval 1.1–1.4]). The RR was 1.1 [0.8–1.6] for estrogens used alone and 1.3 [1.1–1.5] when used in combination with oral progestogens. The risk was significantly greater (p <0.001) with HRT containing synthetic progestins than with HRT containing micronized progesterone, the RRs being 1.4 [1.2–1.7] and 0.9 [0.7–1.2], respectively. When combined with synthetic progestins, both oral and transdermal/percutaneous estrogens use were associated with a significantly increased risk; for transdermal/percutaneous estrogens, this was the case even when exposure was less than 2 years. Our results suggest that, when combined with synthetic progestins, even short‐term use of estrogens may increase breast cancer risk. Micronized progesterone may be preferred to synthetic progestins in short‐term HRT. This finding needs further investigation. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“Previous cohort studies 3,9,11,28-30 and a meta-analysis 31 have shown an increase in risk with increased duration of HRT use.”
Gebbie, A. (2002) · Journal of Family Planning and Reproductive Health Care · doi:10.1783/147118902101196685 · Cited by 1,176
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence
Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004) · JAMA · doi:10.1001/jama.291.1.47 · Cited by 983
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J. A., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 651
Postmenopausal Hormone Therapy and Change in Mammographic Density
Greendale, G. A., Reboussin, B. A., Slone, S., Wasilauskas, C., Pike, M. C., & Ursin, G. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.30 · Cited by 419
Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 417
Fasting glucose is a risk factor for breast cancer: a prospective study.
Muti, P. C., Quattrin, T., Grant, B. J. B., Krogh, V., Micheli, A., Schünemann, H. J., Ram, M., Freudenheim, J. L., Sieri, S., Trevisan, M., et al. (2002) · PubMed · Cited by 362
Self-citationHormone Replacement Therapy in Relation to Breast Cancer
Chen, C.-L. (2002) · JAMA · doi:10.1001/jama.287.6.734 · Cited by 360
Serum insulin-like growth factor-I and breast cancer
Toniolo, P., Bruning, P. F., Akhmedkhanov, A., Bonfrer, J. M. G., Koenig, K. L., Lukanova, A., Shore, R. E., & Zeleniuch-Jacquotte, A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001201)88:5<828::aid-ijc22>3.0.co;2-8 · Cited by 341
Riboli, E. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058097 · Cited by 335
Self-citationThe effect of age and menstrual cycle upon proliferative activity of the normal human breast
Potten, C., Watson, R., Williams, G., Tickle, S., Roberts, S., Harris, M., & Howell, A. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.185 · Cited by 311
Groshong, S. D., Owen, G. I., Grimison, B., Schauer, I. E., Todd, M. C., Langan, T. A., Sclafani, R. A., Lange, C. A., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.11.1593 · Cited by 299
Haftenberger, M., Lahmann, P., Panico, S., Gonzalez, C., Seidell, J., Boeing, H., Giurdanella, M., Krogh, V, Bueno-de-Mesquita, H., Peeters, P., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002396 · Cited by 275
Self-citationRisks of breast and endometrial cancer after estrogen and estrogen–progestin replacement
Persson, I., Weiderpass, E., Bergkvist, L., Bergström, R., & Schairer, C. (1999) · Cancer Causes & Control · doi:10.1023/a:1008909128110 · Cited by 258
and the E3N-EPIC Group, & Clavel-Chapelon, F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600124 · Cited by 229
Self-citationStahlberg, C., Pedersen, A. T., Lynge, E., Andersen, Z. J., Keiding, N., Hundrup, Y. A., Obel, E. B., & Ottesen, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20016 · Cited by 218
Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.
Going, J. J., Anderson, T. J., Battersby, S., & Macintyre, C. C. A. (1988) · Europe PMC (PubMed Central) · Cited by 208
Postmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb, P. A., Titus-Ernstoff, L. T., Egan, K. M., Trentham‐Dietz, A., Baron, J. A., Storer, B. E., Willett, W. C., & Stampfer, M. J. (2002) · PubMed · Cited by 182
Hormone replacement therapy regimens and breast cancer risk
Weiss, L. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02502-4 · Cited by 178
Olsson, H. L., Ingvar, C., & Bladström, A. (2003) · Cancer · doi:10.1002/cncr.11205 · Cited by 169
Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells
Foidart, J.-M., Colin, C., Denoo, X., Desreux, J., Béliard, A., Fournier, S., & Lignieres, B. D. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00042-9 · Cited by 155
Chang, K., Lee, T. T. Y., Linares‐Cruz, G., Fournier, S., & Lignieres, B. D. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57482-2 · Cited by 145
Bellantoni, M. F., Vittone, J. L., Campfield, A., Bass, K. M., Harman, S. M., & Blackman, M. R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768841 · Cited by 144
McManus, M. J., & Welsch, C. W. (1984) · Cancer · Cited by 118
Porch, J. V., Lee, I., Cook, N. R., et al. (2002) · Cancer Causes & Control · doi:10.1023/a:1020617415381 · Cited by 107
Pike, M. C., Ross, R. K., & SPICER, D. V. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009515 · Cited by 67
Jernström, H., Bendahl, P., Lidfeldt, J., Nerbrand, C., Agardh, C., & Samsioe, G. (2003) · Cancer Causes & Control · doi:10.1023/a:1025635720208 · Cited by 57
Bias in Breast Cancer Analyses Due to Error in Age at Menopause
Rockhill, B., Colditz, G. A., & ROSNER, B. A. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010220 · Cited by 54
Campagnoli, C., Biglia, N., Peris, C., & Sismondi, P. (1995) · Gynecological Endocrinology · doi:10.3109/09513599509160194 · Cited by 35
Conjugated estrogens and breast cancer risk.
Campagnoli, C., Ambroggio, S., Biglia, N., et al. (1999) · PubMed · Cited by 27
Magnusson (1999) · doi:10.1002/(sici)1097-0215(19990505)81:3<339::aid-ijc5>3.0.co;2-6
Cited by
Estrogen Carcinogenesis in Breast Cancer
Yager, J. D., & Davidson, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050776 · Cited by 1,862
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693
Self-citationStanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
Brisken, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3518 · Cited by 255
Metadata
- Authors
- Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-11-18
- Volume
- 114
- Issue
- 3
- Pages
- 448-454
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2129012357
- Cited by
- 403
- References
- 40
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.